Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
CDSCO to fast-track trials and approval for COVID19 vaccine
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The first batch will be shipped to the Gamaleya Center for the quality control
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Subscribe To Our Newsletter & Stay Updated
